Skin Cancer: Its causes, mechanism and treatment approaches

Authors

  • Shivangi Raul Department of Biomedical Engineering and Bioinformatics University Teaching Department Chhattisgarh Swami Vivekananda Technical University, Newai, Bhilai, Chhattisgarh, India-491107
  • Ashish Patel Department of Biomedical Engineering and Bioinformatics University Teaching Department Chhattisgarh Swami Vivekananda Technical University, Newai, Bhilai, Chhattisgarh, India-491107
  • Sharmistha Banerjee Department of Biomedical Engineering and Bioinformatics University Teaching Department Chhattisgarh Swami Vivekananda Technical University, Newai, Bhilai, Chhattisgarh, India-491107

Keywords:

BRAF, , V600E, Novel therapy, Melanoma, Natural Compounds

Abstract

Skin cancer is the prevailing problem that exist in society and it affects almost every individual because of the environmental conditions. The rate of skin cancer have been increasing continuously since past few years. Recently in 2021, 1,898,160 new cases of cancer and 608,570 cancer deaths are reported in the United States. Several therapies are available for treatment of skin cancer such as Radiation therapy, Chemotherapy, Immunotherapy, Targeted therapy. There are some conventionally available drugs already in use but are found with various side effects including skin rashes, hair loss, nausea, diarrhoea, vomiting, joint pain, etc. The most important gene responsible for skin cancer is BRAF. Therefore, in future there is hope, in vivo and in vitro evaluation of plant derived phytochemicals (inhibitors) which can establish them to be the most potent V600E-BRAF inhibitors to treat skin cancer. The major cause of development of skin cancer is exposure to UV rays and mutations in gene. The present review is focused on the cause of skin cancer, mechanism of spread, genes responsible, conventional treatment approaches, its side effects and benefit of phytometabolites over the existing drugs.

References

Biol, clavel. Progress in the epidemiological understanding of gene–environment interactions in major diseases: cancer, 2007, 306-317.

American Society of Clinical Oncology, 2020.

Siegel, MPH, Miller, Fuchs, Jemal. Cancer Statistics, 2021, 70:7-33.

Matthews, Li, Qureshi, Weinstock, Cho. Epidemiology of Melanoma, 2017.

Cakir, Genc, Canpolat, Aribal, Berrak. Accuracy of imaging-guided biopsy in diagnosis of malignancy versus infection, 2012; 49, 283-286.

Gordan, Akbani, Liu, Shen, Pasthan. Integrated genomic characterization of endometrial carcinoma, 2013; 497(7447):67-73.

Crythone; Skin Cancer, 2017, 431-434.

Green, Zhu, Ou, Lam, Rauniyar. MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway, 2017; 21, 2829-2841.

Tilli, Krekels, Newman, Ramaekers. Molecular aetiology and pathogenesis of basal cell carcinoma, 2005, 152(6):1108-24.

Verkouteren, Ramdas, Wakkee, Nijsten. Epidemiology of basal cell carcinoma: scholarly review, 2017.

Cadet, Douki. Formation of UV-induced DNA damage contributing to skin cancer development, 2018.

Fahradyan, Howell, Sheth, Tsuha. Updates on the Management of Non-Melanoma Skin Cancer (NMSC), 2017, 5(4):82.

Isola, Eddy, Chen. Biology, Therapy and Implications of Tumor Exosomes in the Progression of Melanoma, 2016.

Reham Alabduljabbar and HalaAlshamlan. Intelligent Multiclass skin cancer detection using convolution neural networks, 2021; 69(1), 831-847.

Didona, Paolino, Bottoni, Cantisani. Non-Melanoma Skin Cancer Pathogenesis Overview, 2018, 6(1):6.

Gallagher, Lee, Bajdik, Borugian. Ultarviolent Radiation, 2010, 51-68.

Qureshi, Zhang, Han. Heterogeneity in Host Risk Factors for Incident Melanoma and Non-Melanoma Skin Cancer in a Cohort of US Women, 2011.

Davis, Dixon, Steinman. Revised Mohs surgery care guidelines for squamous cell carcinoma in-situ are overdue, 2019, 25(3):2.

Jerrant, Johanson, Sheridan, Caffrey. Early detection and treatment of skin cancer, 2000; 62(2):357-68, 375-6, 381-2.

Rogers, Puric, Eberle, Datta, Bodis. Radiotherapy for Melanoma: More than DNA Damage, 2019, 1-9.

Hannen. Immunotherapy of melanoma, 2013; 11; 97-105.

Ranaweera, Tan. Genetics of melanoma, 2011

Tsao, Chin, A., Fisher. Melanoma: from mutations to medicine, 2012; 26(11): 1131–1155.

Davies, R, Philip, Jon, Clegg, Hayley, Dicks, Cooper, Janet Shipley, Darren, Jones, Norman, Trench, D, Giuseppe, Antonio, Adrienne, Andrew, Yuen, L Weber. Mutations of the BRAF gene in human cancer, 2002;417(6892):949-54.

Cheung, Beltran, Massari, T, Montironi. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine, 2017, 31(1): 24–38.

Shiau, Tsao. Molecular Testing in Lung Cancer, 2017, 287-303.

Inamdar GS. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol. 2010;80(5):624-37.

Paluncic J, et al. Roads to melanoma: key pathways and emerging players in melanoma progression and oncogenic signaling. Biochim Biophys Acta. 2016;1863(4):770-84.

Schadendorf, Axel, Santinami, Victoria, Mandala, Vanna, Larkin, Nyakas, Haydon. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial, 2019; 20(5), 701-710

Wesley, ShaliniVerma, P. Patel, A. Davies, Hui Yao,∗ Alexander J. Lazar, D. Aldape.Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma, 2013; 15(2): 220–226.

Eddy, Shah, Chen. Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities, 2021, Volume 10.

Behzad, Ali, Sadaf, Solmaz. The Different Mechanisms of Cancer Drug Resistance: A Brief Review, 2017, 7(3): 339–348.

Tawona N., H., Gerber, H. Hamman and Plessis. Review of Natural Compounds for Potential Skin Cancer Treatment, Molecules, 2014, 19, 11679-11721.

Atanas, Zotchev, M., Claudiu T. Natural products in drug discovery: advances and opportunities, 2021, volume 20.

Milsop, Sivamani, Fazel. Botanical Agents for the Treatment of Nonmelanoma Skin Cancer, 2013, 1-10.

Chinembiri,.H du Plessis, Gerber, H Hamman, Jeanetta. Review of natural compounds for potential skin cancer treatment, 2014; 19(8):11679-721.

Downloads

Published

2022-08-30

How to Cite

Raul, S. ., Patel , A. ., & Banerjee, S. . (2022). Skin Cancer: Its causes, mechanism and treatment approaches. CSVTU International Journal of Biotechnology, Bioinformatics and Biomedical, 7(02), 17–23. Retrieved from https://csvtujournal.in/index.php/ijbbb/article/view/151

Issue

Vol. 7 No. 02 (2022): CSVTU IJBBB

Section

Articles

License

Copyright (c) 2022 CSVTU International Journal of Biotechnology, Bioinformatics and Biomedical

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The Copyright Notice will appear in About the Journal. It should describe for readers and authors whether the copyright holder is the author, journal, or a third party. It should include additional licensing agreements (e.g. CREATIVE COMMONS licenses) that grant rights to readers (see EXAMPLES), and it should provide the means for securing permissions, if necessary, for the use of the journal's content